IRIDEX Corporation (NASDAQ: IRIX) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare IRIDEX Corporation to related businesses based on the strength of its risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Volatility & Risk

IRIDEX Corporation has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, IRIDEX Corporation’s competitors have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.


This table compares IRIDEX Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IRIDEX Corporation -37.62% -16.87% -13.86%
IRIDEX Corporation Competitors -330.26% -33.54% -12.51%

Analyst Recommendations

This is a breakdown of recent ratings and target prices for IRIDEX Corporation and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IRIDEX Corporation 0 0 1 0 3.00
IRIDEX Corporation Competitors 416 2180 3387 122 2.53

IRIDEX Corporation currently has a consensus target price of $20.00, indicating a potential upside of 106.19%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 21.19%. Given IRIDEX Corporation’s stronger consensus rating and higher possible upside, analysts clearly believe IRIDEX Corporation is more favorable than its competitors.

Valuation & Earnings

This table compares IRIDEX Corporation and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
IRIDEX Corporation $42.80 million -$5.81 million -6.42
IRIDEX Corporation Competitors $2.02 billion $430.37 million -56.73

IRIDEX Corporation’s competitors have higher revenue and earnings than IRIDEX Corporation. IRIDEX Corporation is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

47.5% of IRIDEX Corporation shares are held by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 5.0% of IRIDEX Corporation shares are held by company insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

IRIDEX Corporation Company Profile

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Receive News & Stock Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related stocks with our FREE daily email newsletter.